Atrial natriuretic peptide and leptin interactions in healthy men.
ANP
atrial natriuretic peptide
heart failure
insulin resistance
leptin
lipolysis
obesity
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
03
2023
accepted:
09
06
2023
medline:
18
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
Atrial natriuretic peptide (ANP), a hormone secreted from the heart, controls cardiovascular and renal functions including arterial blood pressure and natriuresis. ANP also exerts metabolic effects in adipose tissue, liver and skeletal muscle, and interacts with the secretion of adipokines. We tested the hypothesis that ANP lowers concentrations of the anorexigenic adipokine leptin in healthy humans Human ANP or matching placebo was infused intravenously (iv) into healthy men in a controlled clinical trial. Within 135 minutes of iv ANP infusion, we observed an acute decrease in plasma leptin levels compared to controls. Free fatty acids markedly increased with ANP infusion The study shows that the cardiac hormone ANP reduces the levels of the anorexigenic adipokine leptin in healthy humans, providing further support for ANP as a cardiomyokine in a heart - adipose tissue axis. (registered in the German Clinical Trials Register and the WHO International Clinical Trials Registry Platform was granted under
Identifiants
pubmed: 37455918
doi: 10.3389/fendo.2023.1195677
pmc: PMC10348356
doi:
Substances chimiques
Atrial Natriuretic Factor
85637-73-6
Leptin
0
Types de publication
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1195677Informations de copyright
Copyright © 2023 Daniels, Fischer-Posovszky, Boschmann, Jumpertz-von Schwartzenberg, Müller, Sandforth, Frank-Podlech, Hülskämper, Peter, Wabitsch, Jordan and Birkenfeld.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biochem Pharmacol. 2003 Jun 1;65(11):1883-8
pubmed: 12781340
J Endocrinol. 1997 Dec;155(3):577-85
pubmed: 9488003
PLoS One. 2012;7(8):e43238
pubmed: 22916229
Hypertension. 2018 Aug;72(2):270-276
pubmed: 29941512
Sci Signal. 2017 Jul 25;10(489):
pubmed: 28743802
J Clin Endocrinol Metab. 2005 Jun;90(6):3622-8
pubmed: 15741263
Circulation. 2018 Apr 10;137(15):1614-1631
pubmed: 29632154
Diabetologia. 2016 May;59(5):920-7
pubmed: 26983921
J Clin Invest. 2012 Mar;122(3):1022-36
pubmed: 22307324
Physiol Res. 2007;56(5):503-512
pubmed: 17184148
Redox Biol. 2019 Sep;26:101286
pubmed: 31382214
Int J Obes Relat Metab Disord. 2001 Jan;25(1):8-15
pubmed: 11244452
J Clin Endocrinol Metab. 2006 Dec;91(12):5069-75
pubmed: 16984990
Am J Physiol Endocrinol Metab. 2003 Sep;285(3):E521-6
pubmed: 12736159
J Clin Invest. 2012 Dec;122(12):4675-9
pubmed: 23114600
Diabetes. 2008 Dec;57(12):3199-204
pubmed: 18835931
Nat Rev Cardiol. 2020 Nov;17(11):698-717
pubmed: 32444692
Pharmacol Ther. 2014 Oct;144(1):12-27
pubmed: 24780848
Cardiovasc Endocrinol Metab. 2020 May 15;9(2):49-55
pubmed: 32537565
Endocr Connect. 2015 Sep;4(3):R25-36
pubmed: 26115665
Int J Mol Sci. 2019 Jul 02;20(13):
pubmed: 31269783
Diabetologia. 2007 May;50(5):1038-47
pubmed: 17318625
Trends Endocrinol Metab. 2011 Oct;22(10):404-11
pubmed: 21741267
Diabetes. 2020 May;69(5):823-829
pubmed: 32312898